Our observations suggested that mTOR and MEK co-targeting exerts a synergistic antiproliferative effect in HNSCC cells in vitro and in vivo, and a selective pro-apoptotic impact on PIK3CA expressing HNSCC cells. The gene discussed is MAP2K7; the disease is head and neck squamous cell carcinoma.